

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
You can purchase shares of Insulet (NASDAQ:PODD) through any online brokerage.
Other companies in Insulet’s space includes: Abbott Laboratories (NYSE:ABT), Intuitive Surgical Inc (NASDAQ:ISRG), Medtronic PLC (NYSE:MDT), Stryker Corp (NYSE:SYK) and Boston Scientific Corp (NYSE:BSX).
Insulet has a consensus price target of $232.30.
The stock price for Insulet (NASDAQ: PODD) is $149.26 last updated October 26, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Insulet.
Insulet does not have any upcoming earnings scheduled.
There is no upcoming split for Insulet.
Insulet is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated...